Ezra Holdings Limited (NASDAQ:EZRA – Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 43,558 shares, a growth of 405.0% from the September 30th total of 8,626 shares. Based on an average daily trading volume, of 711,287 shares, the short-interest ratio is presently 0.1 days.
Ezra Stock Down 0.6%
Shares of EZRA traded down $0.01 during trading hours on Tuesday, hitting $2.22. The company had a trading volume of 4,870 shares, compared to its average volume of 765,104. The stock’s 50 day moving average price is $2.54 and its 200 day moving average price is $4.03. Ezra has a 52-week low of $1.75 and a 52-week high of $53.20.
Ezra (NASDAQ:EZRA – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($3.26) earnings per share for the quarter. The company had revenue of $2.11 million during the quarter.
Analysts Set New Price Targets
Several analysts have issued reports on the company. Wall Street Zen lowered Ezra from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ezra in a research note on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Ezra has a consensus rating of “Sell”.
Get Our Latest Analysis on EZRA
Insider Activity at Ezra
In other Ezra news, Director Alex Blumenfrucht sold 8,830 shares of Ezra stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $3.97, for a total transaction of $35,055.10. Following the completion of the sale, the director owned 13 shares of the company’s stock, valued at $51.61. The trade was a 99.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ben Fruchtzweig sold 7,448 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $4.08, for a total value of $30,387.84. Following the transaction, the director owned 5 shares in the company, valued at $20.40. This trade represents a 99.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 34,727 shares of company stock valued at $124,161.
About Ezra
Ezra Ltd. is a medical technology company focused on improving cancer screening through magnetic resonance imaging (MRI) and artificial intelligence. Its platform is designed to help clinicians identify potential cancers earlier by analyzing MRI scans of the body and highlighting areas that may require further evaluation.
The company offers full-body and organ-specific MRI screening services through its technology platform, with the goal of making preventive cancer screening more accessible and efficient.
Further Reading
- Five stocks we like better than Ezra
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
- Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
Receive News & Ratings for Ezra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ezra and related companies with MarketBeat.com's FREE daily email newsletter.
